



Kevin Kavanagh <kavanagh.ent@gmail.com>

FW: question regarding a clinical trial

Conner, Katelyn (McConnell) <Katelyn_Conner@mcconnell.senate.gov>

Tue, Aug 14, 2012 at
11:43 AM

To: "Kevin Kavanagh (kavanagh.ent@gmail.com)" <kavanagh.ent@gmail.com>

Cc: "McClure, Donna (McConnell)" <Donna_McClure@mcconnell.senate.gov>

Dr. Kavanagh,

Please see the response below that I received from the NIH regarding your request. I hope this information is helpful.

Best,

Katelyn

From: Pak, Chol (NIH/OD) [E]
Sent: Tuesday, August 14, 2012 9:39 AM
To: Conner, Katelyn (McConnell)
Cc: Ladt, Elizabeth (McConnell); Pak, Chol (NIH/OD) [E]
Subject: RE: question regarding a clinical trial

Morning Katelyn,

-

Please find NIAID's response to your constituent's question below. Let me know if you need anything else.

Thanks,

Chol

-

The Strategies to Reduce Transmission of Antimicrobial Resistant Bacteria in Intensive Care Units (STAR*ICU) clinical trial, one of the largest studies looking at decreasing the spread of infections in hospitals to date, was supported by the National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health as well as by Merck, Elan Pharmaceuticals, Roche Diagnostics, and Kimberly Clark. The NIAID budget for this study was \$3,141,845.

In the STAR*ICU clinical trial, researchers examined whether actively screening hospital patients for Methicillin-resistant *Staphylococcus aureus* (MRSA) and vancomycin-resistant enterococcus (VRE) and employing greater use of barrier precautions such as gowns and gloves along with hand hygiene among healthcare workers could reduce bacterial transmission in comparison with existing practices. The researchers found no difference in the frequency of infection between those patients who received the expanded interventions and those who did not. The researchers also observed that health care professionals in both the control and intervention groups practiced proper hygiene and used barrier precautions less often than required, suggesting that incomplete compliance by health care providers with recommended hand hygiene procedures and the use of gloves and gowns may have contributed to the findings of the study.

From: Pak, Chol (NIH/OD) [E] []
Sent: Wednesday, August 08, 2012 9:59 AM
To: Conner, Katelyn (McConnell)
Cc: Ladt, Elizabeth (McConnell)
Subject: RE: question regarding a clinical trial

No problem, I'm on it...hopefully we can get something to you in the next couple of days.

Thanks,

Chol

From: Conner, Katelyn (McConnell)[mailto:Katelyn_Conner@mccconnell.senate.gov]
Sent: Wednesday, August 08, 2012 9:50 AM
To: Pak, Chol (NIH/OD) [E]
Cc: Ladt, Elizabeth (McConnell)
Subject: question regarding a clinical trial

Pak,

I have a constituent who would like to receive more information regarding a clinical trial being conducted at the National Institute of Allergy and Infectious Diseases (NIAID). The name of the study is: "Strategies to Reduce Transmission of Antimicrobial Resistant Bacteria in Intensive Care Units (STAR*ICU) Trial," and the Identifier is: NCT00100386 on www.clinicaltrials.gov. Specifically, our constituent would like to know the total federal expenditures available to the study. Is this information listed publically? Or, do you have a suggestion for the best way to find this information. Thank you for any assistance you may be able to offer.

Best,

Katelyn Conner

Office of Senator Mitch McConnell

317 Russell Senate Building

p:

f: (202) 224-2499

Sign up for Senator McConnell's e-Newsletter [HERE](#)





Kevin Kavanagh <kavanagh.ent@gmail.com>

FW: question regarding a clinical trial

Conner, Katelyn (McConnell) <Katelyn_Conner@mcconnell.senate.gov>

Tue, Aug 14, 2012 at
11:43 AM

To: "Kevin Kavanagh (kavanagh.ent@gmail.com)" <kavanagh.ent@gmail.com>

Cc: "McClure, Donna (McConnell)" <Donna_McClure@mcconnell.senate.gov>

Dr. Kavanagh,

Please see the response below that I received from the NIH regarding your request. I hope this information is helpful.

Best,

Katelyn

From: Pak, Chol (NIH/OD) [E]
Sent: Tuesday, August 14, 2012 9:39 AM
To: Conner, Katelyn (McConnell)
Cc: Ladt, Elizabeth (McConnell); Pak, Chol (NIH/OD) [E]
Subject: RE: question regarding a clinical trial

Morning Katelyn,

-

Please find NIAID's response to your constituent's question below. Let me know if you need anything else.

Thanks,

Chol

-

The Strategies to Reduce Transmission of Antimicrobial Resistant Bacteria in Intensive Care Units (STAR*ICU) clinical trial, one of the largest studies looking at decreasing the spread of infections in hospitals to date, was supported by the National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health as well as by Merck, Elan Pharmaceuticals, Roche Diagnostics, and Kimberly Clark. The NIAID budget for this study was \$3,141,845.

In the STAR*ICU clinical trial, researchers examined whether actively screening hospital patients for Methicillin-resistant *Staphylococcus aureus* (MRSA) and vancomycin-resistant enterococcus (VRE) and employing greater use of barrier precautions such as gowns and gloves along with hand hygiene among healthcare workers could reduce bacterial transmission in comparison with existing practices. The researchers found no difference in the frequency of infection between those patients who received the expanded interventions and those who did not. The researchers also observed that health care professionals in both the control and intervention groups practiced proper hygiene and used barrier precautions less often than required, suggesting that incomplete compliance by health care providers with recommended hand hygiene procedures and the use of gloves and gowns may have contributed to the findings of the study.

From: Pak, Chol (NIH/OD) [E] []
Sent: Wednesday, August 08, 2012 9:59 AM
To: Conner, Katelyn (McConnell)
Cc: Ladt, Elizabeth (McConnell)
Subject: RE: question regarding a clinical trial

No problem, I'm on it...hopefully we can get something to you in the next couple of days.

Thanks,

Chol

From: Conner, Katelyn (McConnell)[mailto:Katelyn_Conner@mccconnell.senate.gov]
Sent: Wednesday, August 08, 2012 9:50 AM
To: Pak, Chol (NIH/OD) [E]
Cc: Ladt, Elizabeth (McConnell)
Subject: question regarding a clinical trial

Pak,

I have a constituent who would like to receive more information regarding a clinical trial being conducted at the National Institute of Allergy and Infectious Diseases (NIAID). The name of the study is: "Strategies to Reduce Transmission of Antimicrobial Resistant Bacteria in Intensive Care Units (STAR*ICU) Trial," and the Identifier is: NCT00100386 on www.clinicaltrials.gov. Specifically, our constituent would like to know the total federal expenditures available to the study. Is this information listed publically? Or, do you have a suggestion for the best way to find this information. Thank you for any assistance you may be able to offer.

Best,

Katelyn Conner

Office of Senator Mitch McConnell

317 Russell Senate Building

p:

f: (202) 224-2499

Sign up for Senator McConnell's e-Newsletter [HERE](#)





Kevin Kavanagh <kavanagh.ent@gmail.com>

FW: question regarding a clinical trial

Conner, Katelyn (McConnell) <Katelyn_Conner@mcconnell.senate.gov>

Tue, Aug 14, 2012 at
11:43 AM

To: "Kevin Kavanagh (kavanagh.ent@gmail.com)" <kavanagh.ent@gmail.com>

Cc: "McClure, Donna (McConnell)" <Donna_McClure@mcconnell.senate.gov>

Dr. Kavanagh,

Please see the response below that I received from the NIH regarding your request. I hope this information is helpful.

Best,

Katelyn

From: Pak, Chol (NIH/OD) [E]
Sent: Tuesday, August 14, 2012 9:39 AM
To: Conner, Katelyn (McConnell)
Cc: Ladt, Elizabeth (McConnell); Pak, Chol (NIH/OD) [E]
Subject: RE: question regarding a clinical trial

Morning Katelyn,

-

Please find NIAID's response to your constituent's question below. Let me know if you need anything else.

Thanks,

Chol

-

The Strategies to Reduce Transmission of Antimicrobial Resistant Bacteria in Intensive Care Units (STAR*ICU) clinical trial, one of the largest studies looking at decreasing the spread of infections in hospitals to date, was supported by the National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health as well as by Merck, Elan Pharmaceuticals, Roche Diagnostics, and Kimberly Clark. The NIAID budget for this study was \$3,141,845.

In the STAR*ICU clinical trial, researchers examined whether actively screening hospital patients for Methicillin-resistant *Staphylococcus aureus* (MRSA) and vancomycin-resistant enterococcus (VRE) and employing greater use of barrier precautions such as gowns and gloves along with hand hygiene among healthcare workers could reduce bacterial transmission in comparison with existing practices. The researchers found no difference in the frequency of infection between those patients who received the expanded interventions and those who did not. The researchers also observed that health care professionals in both the control and intervention groups practiced proper hygiene and used barrier precautions less often than required, suggesting that incomplete compliance by health care providers with recommended hand hygiene procedures and the use of gloves and gowns may have contributed to the findings of the study.

From: Pak, Chol (NIH/OD) [E] []
Sent: Wednesday, August 08, 2012 9:59 AM
To: Conner, Katelyn (McConnell)
Cc: Ladt, Elizabeth (McConnell)
Subject: RE: question regarding a clinical trial

No problem, I'm on it...hopefully we can get something to you in the next couple of days.

Thanks,

Chol

From: Conner, Katelyn (McConnell)[mailto:Katelyn_Conner@mccconnell.senate.gov]
Sent: Wednesday, August 08, 2012 9:50 AM
To: Pak, Chol (NIH/OD) [E]
Cc: Ladt, Elizabeth (McConnell)
Subject: question regarding a clinical trial

Pak,

I have a constituent who would like to receive more information regarding a clinical trial being conducted at the National Institute of Allergy and Infectious Diseases (NIAID). The name of the study is: "Strategies to Reduce Transmission of Antimicrobial Resistant Bacteria in Intensive Care Units (STAR*ICU) Trial," and the Identifier is: NCT00100386 on www.clinicaltrials.gov. Specifically, our constituent would like to know the total federal expenditures available to the study. Is this information listed publically? Or, do you have a suggestion for the best way to find this information. Thank you for any assistance you may be able to offer.

Best,

Katelyn Conner

Office of Senator Mitch McConnell

317 Russell Senate Building

p:

f: (202) 224-2499

Sign up for Senator McConnell's e-Newsletter [HERE](#)





Kevin Kavanagh <kavanagh.ent@gmail.com>

FW: question regarding a clinical trial

Conner, Katelyn (McConnell) <Katelyn_Conner@mcconnell.senate.gov>

Tue, Aug 14, 2012 at
11:43 AM

To: "Kevin Kavanagh (kavanagh.ent@gmail.com)" <kavanagh.ent@gmail.com>

Cc: "McClure, Donna (McConnell)" <Donna_McClure@mcconnell.senate.gov>

Dr. Kavanagh,

Please see the response below that I received from the NIH regarding your request. I hope this information is helpful.

Best,

Katelyn

From: Pak, Chol (NIH/OD) [E]
Sent: Tuesday, August 14, 2012 9:39 AM
To: Conner, Katelyn (McConnell)
Cc: Ladt, Elizabeth (McConnell); Pak, Chol (NIH/OD) [E]
Subject: RE: question regarding a clinical trial

Morning Katelyn,

-

Please find NIAID's response to your constituent's question below. Let me know if you need anything else.

Thanks,

Chol

-

The Strategies to Reduce Transmission of Antimicrobial Resistant Bacteria in Intensive Care Units (STAR*ICU) clinical trial, one of the largest studies looking at decreasing the spread of infections in hospitals to date, was supported by the National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health as well as by Merck, Elan Pharmaceuticals, Roche Diagnostics, and Kimberly Clark. The NIAID budget for this study was \$3,141,845.

In the STAR*ICU clinical trial, researchers examined whether actively screening hospital patients for Methicillin-resistant *Staphylococcus aureus* (MRSA) and vancomycin-resistant enterococcus (VRE) and employing greater use of barrier precautions such as gowns and gloves along with hand hygiene among healthcare workers could reduce bacterial transmission in comparison with existing practices. The researchers found no difference in the frequency of infection between those patients who received the expanded interventions and those who did not. The researchers also observed that health care professionals in both the control and intervention groups practiced proper hygiene and used barrier precautions less often than required, suggesting that incomplete compliance by health care providers with recommended hand hygiene procedures and the use of gloves and gowns may have contributed to the findings of the study.

From: Pak, Chol (NIH/OD) [E] []
Sent: Wednesday, August 08, 2012 9:59 AM
To: Conner, Katelyn (McConnell)
Cc: Ladt, Elizabeth (McConnell)
Subject: RE: question regarding a clinical trial

No problem, I'm on it...hopefully we can get something to you in the next couple of days.

Thanks,

Chol

From: Conner, Katelyn (McConnell)[mailto:Katelyn_Conner@mccconnell.senate.gov]
Sent: Wednesday, August 08, 2012 9:50 AM
To: Pak, Chol (NIH/OD) [E]
Cc: Ladt, Elizabeth (McConnell)
Subject: question regarding a clinical trial

Pak,

I have a constituent who would like to receive more information regarding a clinical trial being conducted at the National Institute of Allergy and Infectious Diseases (NIAID). The name of the study is: "Strategies to Reduce Transmission of Antimicrobial Resistant Bacteria in Intensive Care Units (STAR*ICU) Trial," and the Identifier is: NCT00100386 on www.clinicaltrials.gov. Specifically, our constituent would like to know the total federal expenditures available to the study. Is this information listed publically? Or, do you have a suggestion for the best way to find this information. Thank you for any assistance you may be able to offer.

Best,

Katelyn Conner

Office of Senator Mitch McConnell

317 Russell Senate Building

p:

f: (202) 224-2499

Sign up for Senator McConnell's e-Newsletter [HERE](#)

